US-EU Index Rebalances / Quantitative Researcher, Ortex

Dimitris Ioannidis

US-EU Index Rebalances / Quantitative Researcher

Global Financial Data and Analytics Platform

Ortex

ORTEX is a global financial data and analytics platform providing real-time securities lending and short interest data, index rebalance data, holdings and insider transactions, trading signals, corporate actions and news,  stock machine learning and factor scores and other analytics. The majority of the data are downloadable and accessible through APIs.

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/galderma-group-ag" target="_blank" data-smartkarma-citation="entities:43861:1" rel="noopener">Galderma (GALD SW)</a> is one of the largest Global and Swiss Index additions at the August and September 2024 reviews following its recent IPO valued at ~$17bn.</li>
<li>The company is forecasted to get added in the second Global Index at the September 2024 review. Estimated demand is ~$162m and ~5.0 ADV.</li>
<li>The IPO lock-up expiry is forecasted to generate an additional demand of ~$42m and ~1.3 ADV at the December 2024 review. </li>
</ul>



Galderma (GALD SW) is one of the largest Global and Swiss Index additions at the August and September 2024 reviews following its recent IPO valued at ~$17bn.
The company is forecasted to get added in the second Global Index at the September 2024 review. Estimated demand is ~$162m and ~5.0 ADV.
The IPO lock-up expiry is forecasted to generate an additional demand of ~$42m and ~1.3 ADV at the December 2024 review. 


Galderma (GALD): Successful Injection in Swiss & Global Indices

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>Snap-Back rallies have continued in the largest global equity markets (U.S., Japan, and Europe).</li>
<li>Japan's TOPIX is still below 2690-2700 and the EURO STOXX 50 is below 4884, and whether they roll over here or from marginally higher levels, lower highs remain likely.</li>
<li>It all fits with our ongoing belief (since our July 25, 2024 Int'l Compass) that MSCI ACWI is going through a 1- to 4-month pullback/consolidation (we are one month in).</li>
</ul>


Snap-Back rallies have continued in the largest global equity markets (U.S., Japan, and Europe).
Japan's TOPIX is still below 2690-2700 and the EURO STOXX 50 is below 4884, and whether they roll over here or from marginally higher levels, lower highs remain likely.
It all fits with our ongoing belief (since our July 25, 2024 Int'l Compass) that MSCI ACWI is going through a 1- to 4-month pullback/consolidation (we are one month in).


Shift Now to Defensives; Snap-Back Rally Testing Resistance $ACWI $SPX; Neutral Outlook Intact

Switzerland

Galderma Group AG operates as a dermatology company. The Company delivers science-based portfolio of brands and services that span the full spectrum of self-care dermatology market through injectable aesthetics, dermatological skincare, and therapeutic dermatology. Galderma Group serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Galderma (GALD SW)

Galderma (GALD): Successful Injection in Swiss & Global Indices

Galderma (GALD SW) is set to be a major addition to Global and Swiss Indices in August and September 2024 reviews after a $17bn IPO in March 2024.

Dimitris Ioannidis

Shift Now to Defensives; Snap-Back Rally Testing Resistance $ACWI $SPX; Neutral Outlook Intact

Shift Now to Defensives (Health Care, Telecommunications, Utilities, and Consumer Staples); Snap-Back Rally Testing Resistance $ACWI $SPX; Neutral...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Galderma (GALD): Successful Injection in Swiss & Global Indices

​Galderma (GALD SW) is set to be a major addition to Global and Swiss Indices in August and September 2024 reviews after a $17bn IPO in March 2024.

Dimitris Ioannidis

Shift Now to Defensives; Snap-Back Rally Testing Resistance $ACWI $SPX; Neutral Outlook Intact

Shift Now to Defensives (Health Care, Telecommunications, Utilities, and Consumer Staples); Snap-Back Rally Testing Resistance $ACWI $SPX; Neutral...

Vermilion Research

Galderma (GALD SW) is set to be a major addition to Global and Swiss Indices in August and September 2024 reviews after a $17bn IPO in March 2024.